Cloud Infrastructures for In Silico Drug Discovery: Economic and Practical Aspects

Cloud computing opens new perspectives for small-medium biotechnology laboratories that need to perform bioinformatics analysis in a flexible and effective way. This seems particularly true for hybrid clouds that couple the scalability offered by general-purpose public clouds with the greater control and ad hoc customizations supplied by the private ones. A hybrid cloud broker, acting as an intermediary between users and public providers, can support customers in the selection of the most suitable offers, optionally adding the provisioning of dedicated services with higher levels of quality. This paper analyses some economic and practical aspects of exploiting cloud computing in a real research scenario for the in silico drug discovery in terms of requirements, costs, and computational load based on the number of expected users. In particular, our work is aimed at supporting both the researchers and the cloud broker delivering an IaaS cloud infrastructure for biotechnology laboratories exposing different levels of nonfunctional requirements.

[1]  Jacob D. Durrant,et al.  Molecular dynamics simulations and drug discovery , 2011, BMC Biology.

[2]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. , 2001, Advanced drug delivery reviews.

[3]  Sanjay P. Ahuja,et al.  The State of High Performance Computing in the Cloud , 2012 .

[4]  Randy H. Katz,et al.  Above the Clouds: A Berkeley View of Cloud Computing , 2009 .

[5]  Philippe Olivier Alexandre Navaux,et al.  Evaluating High Performance Computing on the Windows Azure Platform , 2012, 2012 IEEE Fifth International Conference on Cloud Computing.

[6]  Andrea Clematis,et al.  Image-Based Surface Matching Algorithm Oriented to Structural Biology , 2011, IEEE/ACM Transactions on Computational Biology and Bioinformatics.

[7]  Andrea Clematis,et al.  A QoS-aware broker for hybrid clouds , 2012, Computing.

[8]  Averill M. Law,et al.  Simulation Modeling and Analysis , 1982 .

[9]  Peter Gedeck,et al.  Exploiting QSAR models in lead optimization. , 2008, Current opinion in drug discovery & development.

[10]  B Testa,et al.  In silico pharmacology for drug discovery: applications to targets and beyond , 2007, British journal of pharmacology.

[11]  L. Milanesi,et al.  Systems biology of the metabolic network regulated by the Akt pathway. , 2012, Biotechnology advances.

[12]  Andrea Clematis,et al.  Delivering Cloud Services with QoS Requirements: An Opportunity for ICT SMEs , 2012, GECON.

[13]  Jianpeng Ma,et al.  CHARMM: The biomolecular simulation program , 2009, J. Comput. Chem..

[14]  Martin Hofmann-Apitius,et al.  In silico drug discovery approaches on grid computing infrastructures. , 2010, Current clinical pharmacology.

[15]  Joo Chuan Tong,et al.  Recent advances in computer-aided drug design , 2009, Briefings Bioinform..

[16]  David S. Goodsell,et al.  A semiempirical free energy force field with charge‐based desolvation , 2007, J. Comput. Chem..

[17]  Rajkumar Buyya,et al.  Cloud Computing Principles and Paradigms , 2011 .

[18]  Geoffrey C. Fox,et al.  IEEE TRANSACTIONS ON JOURNAL NAME, MANUSCRIPT ID 1 Cloud Technologies for Bioinformatics Applications , 2022 .

[19]  Radu Prodan,et al.  Double Auction-based Scheduling of Scientific Applications in Distributed Grid and Cloud Environments , 2011, Journal of Grid Computing.

[20]  Wu Zhang,et al.  A Scheduling Algorithm for Private Clouds , 2011 .

[21]  Rajkumar Buyya,et al.  Environment-conscious scheduling of HPC applications on distributed Cloud-oriented data centers , 2011, J. Parallel Distributed Comput..

[22]  Jingfa Xiao,et al.  Bioinformatics clouds for big data manipulation , 2012, Biology Direct.

[23]  J. Gready,et al.  Combining docking and molecular dynamic simulations in drug design , 2006, Medicinal research reviews.

[24]  Stanley J. Watowich,et al.  Using Free Energy of Binding Calculations To Improve the Accuracy of Virtual Screening Predictions , 2011, J. Chem. Inf. Model..

[25]  J. An,et al.  Structure-based virtual screening of chemical libraries for drug discovery. , 2006, Current opinion in chemical biology.

[26]  L. Stein.  The case for cloud computing in genome informatics , 2010, Genome Biology.

[27]  Matthew P. Repasky,et al.  Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. , 2006, Journal of medicinal chemistry.

[28]  Craig A. Lee.  A perspective on scientific cloud computing , 2010, HPDC '10.

[29]  R. Abagyan,et al.  Pocketome via Comprehensive Identification and Classification of Ligand Binding Envelopes* , 2005, Molecular & Cellular Proteomics.

[30]  Simon S. J. Cross,et al.  Improved FlexX Docking Using FlexS-Determined Base Fragment Placement , 2005, J. Chem. Inf. Model..

[31]  Carsten Kutzner,et al.  GROMACS 4:  Algorithms for Highly Efficient, Load-Balanced, and Scalable Molecular Simulation. , 2008, Journal of chemical theory and computation.

[32]  Shane C. Burgess,et al.  Transcriptome-Based Differentiation of Closely-Related Miscanthus Lines , 2012, PloS one.

[33]  Konstantinos Krampis,et al.  Cloud BioLinux: pre-configured and on-demand bioinformatics computing for the genomics community , 2012, BMC Bioinformatics.

[34]  Dariusz Plewczynski,et al.  In Silico Prediction of SARS Protease Inhibitors by Virtual High Throughput Screening , 2007, Chemical biology & drug design.

[35]  E. Kunkel.  Systems biology in drug discovery , 2004, Nature Biotechnology.

[36]  Ivan Merelli,et al.  Virtual screening pipeline and ligand modelling for H5N1 neuraminidase. , 2009, Biochemical and biophysical research communications.

[37]  Sandeep Grover,et al.  Topical dorzolamide for the treatment of cystoid macular edema in patients with retinitis pigmentosa. , 2006, American journal of ophthalmology.

[38]  Campbell McInnes,et al.  Virtual screening strategies in drug discovery. , 2007, Current opinion in chemical biology.

[39]  Fabio Panzieri,et al.  QoS–Aware Clouds , 2010, 2010 IEEE 3rd International Conference on Cloud Computing.

[40]  Ivan Merelli,et al.  Static and dynamic interactions between GALK enzyme and known inhibitors: guidelines to design new drugs for galactosemic patients. , 2013, European journal of medicinal chemistry.

[41]  Jordi Torres,et al.  Building Online Performance Models of Grid Middleware with Fine-Grained Load-Balancing: A Globus Toolkit Case Study , 2007, EPEW.

[42]  Virgílio A. F. Almeida,et al.  Performance by Design - Computer Capacity Planning By Example , 2004 .

[43]  I. Kuntz,et al.  DOCK 6: combining techniques to model RNA-small molecule complexes. , 2009, RNA.

[44]  Anton Nekrutenko,et al.  Galaxy CloudMan: delivering cloud compute clusters , 2010, BMC Bioinformatics.

[45]  Xiaowu Chen,et al.  Discovery and development of GS 4104 (oseltamivir): an orally active influenza neuraminidase inhibitor. , 2000, Current medicinal chemistry.

[46]  David R. Riley,et al.  CloVR: A virtual machine for automated and portable sequence analysis from the desktop using cloud computing , 2011, BMC Bioinformatics.

[47]  N. Jacq,et al.  Grid-Enabled High-Throughput In Silico Screening Against Influenza A Neuraminidase , 2006, IEEE Transactions on NanoBioscience.

[48]  Shajulin Benedict.  Performance issues and performance analysis tools for HPC cloud applications: a survey , 2012, Computing.

[49]  Elisabetta Ronchieri,et al.  WNoDeS, a tool for integrated Grid and Cloud access and computing farm virtualization , 2011 .

[50]  A. Venturini,et al.  The HPC Testbed of the Italian Grid Infrastructure , 2013, 2013 21st Euromicro International Conference on Parallel, Distributed, and Network-Based Processing.

[51]  Jane Yeo,et al.  Amprenavir in Combination with Lamivudine and Zidovudine versus Lamivudine and Zidovudine Alone in HIV-1-Infected Antiretroviral-Naive Adults , 1999, Antiviral therapy.

[52]  Luciano Milanesi,et al.  Homology modeling in tandem with 3D-QSAR analyses: a computational approach to depict the agonist binding site of the human CB2 receptor. , 2011, European journal of medicinal chemistry.

[53]  D. M. Ryan,et al.  Rational design of potent sialidase-based inhibitors of influenza virus replication , 1993, Nature.

[54]  Andrew Simon Bell,et al.  Sildenafil (VIAGRATM), a potent and selective inhibitor of type 5 cGMP phosphodiesterase with utility for the treatment of male erectile dysfunction , 1996 .

[55]  Michael C. Schatz,et al.  Cloud Computing and the DNA Data Race , 2010, Nature Biotechnology.

[56]  Vibhav Garg,et al.  Cloud computing approaches to accelerate drug discovery value chain. , 2011, Combinatorial chemistry & high throughput screening.

[57]  Brian K. Shoichet,et al.  ZINC - A Free Database of Commercially Available Compounds for Virtual Screening , 2005, J. Chem. Inf. Model..

[58]  Laxmikant V. Kalé,et al.  Scalable molecular dynamics with NAMD , 2005, J. Comput. Chem..

[59]  Ling Kang,et al.  A hierarchical method for molecular docking using cloud computing. , 2012, Bioorganic & medicinal chemistry letters.

[60]  Alessandro Orro,et al.  Molecular Interaction Studies of HIV-1 Matrix Protein p17 and Heparin , 2012, The Journal of Biological Chemistry.

[61]  David S. Goodsell,et al.  AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility , 2009, J. Comput. Chem..

[62]  Peter J. Tonellato,et al.  Cost-Effective Cloud Computing: A Case Study Using the Comparative Genomics Tool, Roundup , 2010, Evolutionary bioinformatics online.